Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 56, Issue 6, 2007, Pages 2094-2096

  Ji, Hyeon Ju ^a   Kim, Sung Il ^b   Lee, Jun Hee ^b   Lee, Sang Il ^c   Yoo, Wan Hee ^d   Choe, Jung Yoon ^e   Chung, Seung Hie ^e   Lee, Jisoo ^f   Lee, You Hyun ^f   Lee, Shin Seok ^g   Yoon, Hyun Jung ^g   Yoon, Chong Hyeon ^a   Kim, Ho Youn ^a   Park, Sung Hwan ^a  

^a The Catholic University of Korea   (South Korea)

^b Pusan Chatolic University   (South Korea)

^c Gyeongsang National University   (South Korea)

^d Chonbuk National University   (South Korea)

^e Catholic University of Daegu   (South Korea)

^f Ewha Womans University   (South Korea)

^g Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BUCILLAMINE; COLESTYRAMINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; STEROID; ANTIRHEUMATIC AGENT; ISOXAZOLE DERIVATIVE;

ADULT; ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; KOREA; LOW DRUG DOSE; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; CHEMICALLY INDUCED DISORDER; ETHNOLOGY; MIDDLE AGED; RISK FACTOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; ISOXAZOLES; KOREA; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RISK FACTORS;

EID: 34447517421     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22666     Document Type: Article

References (10)

1. Li EK, Tam LS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 2004;26:447-59.
2. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60: 913-23.
3. Kalden JR, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 2003;48:1513-20.
4. Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2005;52: 554-62.
5. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004;363(9407):461.
6. Kamata Y, Nara H, Kamimura T, Haneda K, Iwamoto M, Masuyama J, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004;43:1201-4.
7. Takeishi M, Akiyama Y, Akiba H, Adachi D, Hirano M, Mimura T. Leflunomide induced acute interstitial pneumonia. J Rheumatol 2005;32:1160-3.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40:1829-37.
10. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006;54:1435-9.